Exor becomes a long-term investor in Philips supporting the company’s strategy


August 14, 2023

Joint announcement from Philips and Exor
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, and Exor N.V. (AEX: EXO), the Netherlands-based diversified holding company, announce they have entered into a relationship agreement as a result of which Exor has bought a 15% shareholding in Philips. This investment by Exor is fully supportive of Philips’ leadership, strategy and value creation potential and provides for Exor to nominate one member to the Supervisory Board of Philips.

Philips’ strategy and value creation plan with sustainable impact is based on its purpose to improve people's health and well-being through meaningful innovation. The company has leading market positions in attractive health technology market segments enabled by an innovative portfolio and strong customer base.

Exor aims to build great companies providing stable and committed support for their long-term value creation plans. The discussions between Exor and Philips were initiated in the context of Exor’s stated interest in increasing its presence in the healthcare and technology sectors. Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases and an agreement with a major financial institution.

The relationship agreement includes Exor’s commitment to be a long-term minority investor and the right to propose one member to the Supervisory Board, as well as several customary conditions. While Exor does not plan to buy further Philips shares in the short term, over time the relationship agreement provides for Exor, at its discretion, to increase its participation to a maximum limit of 20% of Philips’ outstanding ordinary share capital. The relationship agreement can be accessed here.

Roy Jakobs, CEO of Royal Philips, said: “Exor’s investment in Philips, their long-term outlook and increased focus on healthcare and technology, fit well with our strategy and substantial value creation potential. With our market leadership positions and people-centric innovation capabilities, Philips is well positioned to deliver on our purpose to improve the health and well-being of people, creating value for all stakeholders.”

Feike Sijbesma, Chairman of the Supervisory Board of Royal Philips, said: “We welcome Exor as a long-term investor in Philips. They have a successful track record and clear strategy to grow and develop in healthcare and technology. Exor’s substantial investment underlines their confidence in Philips’ transformation into a healthcare technology company and its growth and value potential.”

John Elkann, Exor’s CEO, commented: “The path of change taken by Philips in recent years has created a company that combines two areas – healthcare and technology – to which we are committed. Our discussions have confirmed the strong and positive alignment between our long-term, supportive approach to our companies and Philips’ ambitious plans under the chairmanship of Feike Sijbesma and the executive team led by Roy Jakobs.”

For further information, please contact:

Philips Global Media Relations
Steve Klink
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Philips Investor Relations
Leandro Mazzoni
Tel.: +31 20 5977055
E-mail: leandro.mazzoni@philips.com

Exor Media Relations
Tel.: + 31 20 240 2221
E-mail: media@exor.com

Exor Investor Relations
Tel.: + 31 20 240 2222
E-mail: ir@exor.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Exor
Exor N.V. (AEX: EXO), is the Netherlands based diversified holding company, listed on the AEX. For over a century, Exor has built great companies and made successful investments worldwide with a culture that combines entrepreneurial spirit and financial discipline. With a Net Asset Value of around EUR 33 billion, its portfolio is principally made up of companies in which Exor is the largest shareholder including Ferrari, Stellantis and CNH Industrial. More recently, in the healthcare sector Exor has made important investments in Institut Mérieux and in Lifenet Healthcare while in the technology sector it has become the largest single shareholder in VIA Transportation Inc.

Forward-looking statements
This statement contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachments

  • A Philips Azurion Image-Guided Therapy system in use
  • Philips CT scanner operated by doctor and tech support in the control room
  • A nurse reassuring a child and mother before the MRI exam by means of Pediatric Coaching
  • A nurse using EPIQ Elite Ultrasound system
  • Mother and kid brushing with the new Sonicare for Kids Pets


Exor becomes a long-term investor in Philips supporting the company’s strategy

THỦ THUẬT HAY

Những thao tác cơ bản với phần mềm 7-Zip

Nếu còn đang băn khoăn, lưỡng lự giữa việc lựa chọn một phần mềm hỗ trợ nén và giải nén dữ liệu thì có một lời khuyên cho các bạn, đó là hãy sử dụng 7-Zip, một trong những công cụ nén file mạnh mẽ và ưu việt nhất hiện

Sửa lỗi Chrome Unresponsive (trang không phản hồi)

Lỗi này được hiển thị qua thông báo Chrome Unresponsive đồng thời kèm theo hai tùy chọn là 'Kill pages' hoặc 'Wait', nên nhiều người dùng thường gọi đây là lỗi 'Kill pages' trên Chrome, lỗi Chrome bắt chờ hoặc lỗi

Cách tắt thông báo “Is Displaying Over Other Apps” trên Android Oreo

Trong phiên bản Oreo, Android đã cho hiển thị thông báo hệ thống để người dùng biết ứng dụng nào đang chạy đồng thời trong ứng dụng khác. Điều này vô cùng hữu ích nhưng một số người dùng lại không quan tâm và đôi khi

Snapdragon 8 Gen 2 sẽ tập trung vào chất lượng nhiều hơn

Qualcomm đã thông báo rằng họ sẽ tung ra chipset Snapdragon 8 Gen 2 thế hệ tiếp theo vào ngày 15 tháng 11 năm 2022. Trước khi Snapdragon 8 Gen 2 ra mắt thì một số thông tin chi tiết về SoC đã được tiết lộ cho thấy con

ĐÁNH GIÁ NHANH

So sánh iPhone 13 và iPhone 13 Pro: Điểm khác biệt giữa hai sản phẩm này là gì?

Mới đây, Apple đã chính thức giới thiệu dòng iPhone 13 Series mới nhất với nhiều cải tiến, nâng cấp hấp dẫn. Trong bài viết này, chúng ta hãy cùng so sánh iPhone 13 và iPhone 13 Pro để nhận biết được sự khác nhau giữa

Đánh giá thời lượng pin Samsung Galaxy A03s: Đứng đầu phân khúc giá

Galaxy A03s chỉ nằm trong phân khúc giá rẻ nhưng lại sở hữu viên pin dung lượng khủng 5.000 mAh so với các đối thủ. Vậy dung lượng trên có đủ để đáp ứng nhu cầu sử dụng của người dùng hay không? Hãy cùng chúng tôi đánh

Đánh giá OnePlus Nord N10 5G: 5G vẫn là điểm đáng giá nhất trên chiếc máy 8 triệu đồng

Ngoài 5G, OnePlus Nord N10 không có nhiều yếu tố đủ mạnh mẽ để cạnh tranh với các đối thủ trong tầm giá. Đây không phải là sản phẩm có pin lớn và màn hình đẹp như Galaxy M51, không có cấu hình phá giá như máy Xiaomi,